|1.||Masamune, Atsushi: 3 articles (10/2015 - 10/2013)|
|2.||Ludwig, Maren: 2 articles (10/2015 - 10/2013)|
|3.||Kakuta, Yoichi: 2 articles (10/2015 - 10/2013)|
|4.||Kume, Kiyoshi: 2 articles (10/2015 - 10/2013)|
|5.||Witt, Heiko: 2 articles (10/2015 - 10/2013)|
|6.||Nakano, Eriko: 2 articles (10/2015 - 10/2013)|
|7.||Shimosegawa, Tooru: 2 articles (10/2015 - 10/2013)|
|8.||Braun, Markus: 2 articles (10/2015 - 10/2013)|
|9.||Sahin-Tóth, Miklós: 2 articles (10/2015 - 10/2013)|
|10.||Paliwal, Sumit: 2 articles (12/2014 - 10/2013)|
01/01/2012 - "Tumors were chemically induced in BALB/c mice and tumor progression was divided into Phases I, II and III. Phase I tumors exhibited a large number of mast cells, which increased in phase II and remained unchanged in phase III. The expression of mouse mast cell protease (mMCP)-4, mMCP-5, mMCP-6, mMCP-7, and carboxypeptidase A were analyzed at the 3 stages. "
01/01/1994 - "Prodrug forms of MTX, e.g., MTX alpha-phenylalanine, which can be activated by carboxypeptidase A-monoclonal antibody conjugates, offer promise for improved efficacy of the drug by selective targeting to tumors. "
05/05/2005 - "This study primarily focuses on the synthesis and characterization of methoxypoly(ethylene glycol)-modified carboxypeptidase A (CPA) for solid tumor targeting. "
05/05/2005 - "Methoxypoly(ethylene glycol)-conjugated carboxypeptidase A for solid tumor targeting: part II: pharmacokinetics and biodistribution in normal and tumor-bearing rodents."
05/05/2005 - "Methoxypoly(ethylene glycol)-conjugated carboxypeptidase A for solid tumor targeting: part I: synthesis and characterization."
|2.||Pancreatic Neoplasms (Pancreatic Cancer)
04/01/1991 - "When the reactivity of IgG in sera with the purified carboxypeptidase A was measured, the detection rates for lung, ovary, larynx, uterus, and liver cancer were more than 50%, while the rates for stomach and breast cancer were around 30%, and pancreatic cancer, benign diseases, and normal controls were minimally detected."
05/01/2012 - "To determine the serum levels of procarboxypeptidase A (pro-CPA) and carboxypeptidase A (CPA) in patients with acute and chronic pancreatitis and pancreatic cancer. "
07/01/2014 - "An abstract presented in ASCO 2014 by Orlowski et al. introduced the potential use of an elevated serum procarboxypeptidase A (PCPA) and high ratios of PCPA to free carboxypeptidase A (FCPA) in enhancing the diagnostic efficacy of pancreatic cancer either alone or with CA19-9 (Abstract #4118). "
03/01/2008 - "We profiled 18 pancreatic cancer cases and 19 controls and 19 ovarian cancer cases and 20 controls for the following proteins: a disintegrin and metalloprotease 8, CA-125, CA 19-9, carboxypeptidase A1, carcinoembryonic antigen, connective tissue growth factor, epidermal growth factor receptor, epithelial cell adhesion molecule, Her2, galectin-1, insulin-like growth factor 2, interleukin-1alpha, interleukin-7, mesothelin, macrophage migration inhibitory factor, osteopontin, secretory leukocyte peptidase inhibitor, tumor necrosis factor alpha, vascular endothelial growth factor, and chitinase 3-like 1. Probes for CA-125 were present in 3 of the multiplex panels. "
|4.||Cystic Fibrosis (Mucoviscidosis)
11/20/1980 - "Chromatography of carboxypeptidase A and B activity of cultured skin fibroblasts: relationship to cystic fibrosis."
07/01/1978 - "Carboxypeptidase A activity of cultured skin fibroblasts and relationship to cystic fibrosis."
07/01/1978 - "Trypsin treatment of carboxypeptidase A produced a form of the enzyme having a higher KM value for both control and cystic fibrosis fibroblasts. "
07/01/1978 - "Properties of carboxypeptidase A of cultured skin fibroblasts from control and cystic fibrosis patients were studied using alpha-N-carbobenzoxy-L-glutamyl-L-tyrosine as substrate. "
12/14/2014 - "Several studies have shown that, rather than mutations in trypsinogens, variants in serine protease inhibitor kazal type 1, cathepsin B, chymotrypsin C, cystic fibrosis transmembrane regulator, and carboxypeptidase A1, predict risk of TCP. "
01/01/2002 - "Moreover, incubation studies with purified pancreatic enzymes that are present in the intestine were performed to determine the most active enzymes responsible for the intestinal cleavage of IGF-I. IGF-I was mainly degraded by chymotrypsin (t(1/2) = 2.7 min) and trypsin (t(1/2) = 34.6 min), whereas in the presence of aminopeptidase M and carboxypeptidase A IGF-I was stable up to 90 min. IGF-I was degraded in flushings from the jejunum, ileum, and colon. "
|1.||Carboxypeptidases A (Carboxypeptidase A)
|6.||Serine Proteases (Serine Protease)
|7.||Ethylene Glycol (Monoethylene Glycol)
|9.||CD13 Antigens (Alanine Aminopeptidase)
|10.||Insulin-Like Growth Factor I (IGF-1)